Clinical Trials
54 trialsPhase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies
Presage Biosciences
Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma
Fox Chase Cancer Center
Efficacy and Safety of Neoadjuvant Cadonilimab Plus High-Dose Recombinant Human Interferon α1b in Stage III/IV Melanoma.
Xijing Hospital
Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study
Indiana University
RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis
University of Pittsburgh
Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases
H. Lee Moffitt Cancer Center and Research Institute
Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma
Mayo Clinic
Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma
H. Lee Moffitt Cancer Center and Research Institute
177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors
Radiopharm Theranostics, Ltd
Exercise to Boost Response to Checkpoint Blockade Immunotherapy
H. Lee Moffitt Cancer Center and Research Institute
Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Mel 70
University of Virginia
Zr89 + PET Companion Trial
Abramson Cancer Center at Penn Medicine
Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of Melanoma
Mayo Clinic
FAST-CR
The University of Hong Kong-Shenzhen Hospital
MELRIV-1
Centre Jean Perrin
18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases
University of Southern California
MB-CART20.1 Melanoma
Miltenyi Biomedicine GmbH
Allogeneic Gammadelta T Cells Combined With Interferon-α1b or PD-1 Monoclonal Antibody in Stage III-IV Amenable to Surgical Resection Melanoma
Xijing Hospital
Tilmanocept
University of Lausanne Hospitals
Mel61
University of Virginia
A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid Tumors
Shanghai Yunying Medical Technology
Autologous T Cells Expressing MET scFv CAR (RNA CART-cMET)
University of Pennsylvania
MPAK
Columbia University
Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery
Ohio State University Comprehensive Cancer Center
Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery
Rutgers, The State University of New Jersey
pDNA Intralesional Cancer Vaccine for Cutaneous Melanoma
TuHURA Biosciences, Inc.
A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes
Yale University
CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia
Presage Biosciences
YSCH-01
Shanghai Fengxian District Central Hospital
Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic Melanoma
Yale University
Prevention of Recurrence and Metastasis in Genetically High-Risk Melanomas
Case Comprehensive Cancer Center
IGTM-101
Hospital Italiano de Buenos Aires
MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery
Mayo Clinic
Treatment of Malignant Melanoma With GPA-TriMAR-T Cell Therapy
Timmune Biotech Inc.
Fluorescence Imaging in Sentinel Lymph Node Biopsy for Breast Cancer and Melanoma
Washington University School of Medicine
Aldesleukin Imaging in Viewing Tumor Growth in Patients With Stage IV Melanoma Receiving Ipilimumab or Pembrolizumab Therapy
Mayo Clinic
TITAN
Hoffmann-La Roche
PET Quantitative Assessments of Solid Tumor Response to Immune Checkpoint Blockade Therapy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery
Mayo Clinic
Pilot Study Evaluating Sulforaphane in Atypical Nevi-Precursor Lesions
University of Pittsburgh
Immunogenicity and Biomarker Analysis of Neoadjuvant Ipilimumab for Melanoma
University of Pittsburgh
Pilot Study of IFN α2b for Melanoma Patients
University of Pittsburgh
IMCgp100 in Advanced Unresectable Melanoma
University of Pennsylvania
Mel55
University of Virginia
Proof of Concept Study With an Endothelin Receptor B Inhibitor (BQ-788) for Human Melanoma
MelCure SA
Genistein and Interleukin-2 in Treating Patients With Metastatic Melanoma or Kidney Cancer
Northwestern University
Vaccine Therapy and Resiquimod in Treating Patients With Stage II, Stage III, or Stage IV Melanoma That Has Been Completely Removed by Surgery
Mayo Clinic